Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma

Journal of Asthma

Volumn 48, Issue 9, 2011, Pages 965-973

  Bachert, Claus ^a   Maspero, Jorge ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CABA   (Argentina)

Author keywords

Desloratadine; Fexofenadine; Histamine receptors; Levocetirizine; Quality of life; Rupatadine

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE RECEPTOR; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; MONTELUKAST; PLACEBO; PROTEIN KINASE C; PSEUDOEPHEDRINE; RUPATADINE;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HUMAN; IN VITRO STUDY; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; THERAPY EFFECT; TREATMENT RESPONSE;

ASTHMA; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RECEPTORS, HISTAMINE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 80054917722     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2011.616616     Document Type: Article

References (67)

1. Taegtmeyer AB, Steurer-Stey C, Spertini F, Bircher A, Helbling A, Miedinger D, Schafroth S, Scherer K, Leuppi JD. Allergic rhinitis in patients with asthma: the Swiss LARA (Link Allergic Rhinitis in Asthma) survey. Curr Med Res Opin 2009; 25:1073-1080
2. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, FokkensW, Kemp J, Ohta K, Price D, Bousquet J, for the ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62(Suppl. 84):1-41
3. Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 2010; 10:194-201
4. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy 2003; 58:691-706
5. Gelfand EW. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am J Med 2002; 113(Suppl. 9A):2S-7S
6. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993; 151:3853-3865
7. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-480
8. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, At-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, OHehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(Suppl. 86):8-160
9. Asher MI, Montefort S, Bjorksten B, Björkstén B, Lai CK, Strachan DP,Weiland SK,Williams H, for the ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-743
10. Wang D, Clement P, Smitz J, De Waele M, Derde MP. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995; 106: 278-285
11. Georgitis JW, Stone BD, Gottschlich G. Inflammatory cells and mediator release during ragweed challenge: correlation between histamine content in nasal secretions and appearance of inflammatory cells. Ann Allergy 1992; 68:413-418
12. Jarjour NN, Calhoun WJ, Schwartz LB, Busse WW. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis 1991; 144:83-87
13. Casolaro V, Galeone D, Giacummo A, Sanduzzi A, Melillo G, Marone G. Human basophil/mast cell releasability. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis 1989; 139:1375-1382
14. Jacobi HH, Skov PS, Poulsen LK, Malling HJ, Mygind N. Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol 1999; 103(5 Pt. 1):768-772
15. McLeod RL, Mingo GG, Herczku C, DeGennaro-Culver F, Kreutner W, Egan RW, Hey JA. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999; 13:391-399
16. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(Suppl. 65):21-27
17. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004; 114: 997-1008
18. Naclerio RM, Baroody F. Understanding the inflammatory processes in upper allergic airway disease and asthma. J Allergy Clin Immunol 1998; 101(2 Pt. 2):S345-S351
19. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7:41-53
20. Yamashita M, Fukui H, Sugama K, Horio Y, Ito S, Mizuguchi H,Wada H. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci USA 1991; 88:11515-11519
21. Jutel M, Blaser K, Akdis CA. Histamine in chronic allergic responses. J Investig Allergol Clin Immunol 2005; 15:1-8
22. Hill SJ, Emson PC, Young JM. The binding of [[3H]]mepyramine to histamine H1 receptors in guinea-pig brain. J Neurochem 1978; 31:997-1004
23. Driver AG, Mustafa SJ. Correlation of histamine H1 receptor function and [[3H]]mepyramine binding in porcine tracheal tissue. Eur J Pharmacol 1987; 139:287-295
24. Hill SJ, Young JM. Characterization of [[3H]]mepyramine binding to the longitudinal muscle of guinea pig small intestine. Mol Pharmacol 1981; 19:379-387
25. Kondo M, Taniyama K, Tanaka C. Histamine H1-receptors in the guinea-pig urinary bladder. Eur J Pharmacol 1985; 114:89-92
26. Hide M, Fukui H, Watanabe T, Wada H, Yamamoto S. Histamine H1- receptor in endothelial and smooth muscle cells of guinea-pig aorta. Eur J Pharmacol 1988; 148:161-169
27. Villemain FM, Bach JF, Chatenoud LM. Characterization of histamine H1 binding sites on human T lymphocytes by means of 125I-iodobolpyramine. Preferential expression of H1 receptors on CD8 T lymphocytes. J Immunol 1990; 144:1449-1454
28. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci USA 1996; 93:13316-13320
29. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236:385-390
30. van der Werf JF, Timmerman H. The histamine H3 receptor: a general presynaptic histaminergic regulatory system? Trends Pharmacol Sci 1989; 10:159-162
31. Takeshita K, Sakai K, Bacon KB, Gantner F. Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 2003; 307:1072-1078
32. Daneshmand MA, Keller RS, Canver MC, Canver AC, Canver CC. Histamine H1 and H2 receptor-mediated vasoreactivity of human internal thoracic and radial arteries. Surgery 2004; 136(2): 458-463
33. Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol 1982; 49: 249-251
34. Kim J, Ogai A, Nakatani S, Hashimura K, Kanzaki H, Komamura K, Asakura M, Asanuma H, Kitamura S, Tomoike H, Kitakaze M. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol 2006; 48:1378-1384
35. McCord JL, Beasley JM, Halliwill JR. H2-receptor-mediated vasodilation contributes to postexercise hypotension. J Appl Physiol 2006; 100:67-75
36. van der Vliet A, Bast A, Timmerman H. Autoinhibition of histamine release by H3 receptors in rat brain cortex depends on stimulation frequency. Agents Actions 1990; 30:206-209
37. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302:832-837
38. Timmerman H. Histamine H3 ligands: just pharmacological tools or potential therapeutic agents? J Med Chem 1990; 33:4-11
39. Teuscher C, Subramanian M, Noubade R, Gao JF, Offner H, Zachary JF, Blankenhorn EP. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci USA 2007; 104: 10146-10151
40. Liu C, Wilson SJ, Kuei C, Lovenberg TW. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 2001; 299:121-130
41. Bachert C. Histamine-a major role in allergy? Clin Exp Allergy 1998; 28:15-19
42. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002; 57:287-296
43. Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther 2009; 31:921-944
44. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369-1377
45. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997; 27:559-567
46. Holden NS, Gong W, King EM, Kaur M, Giembycz MA, Newton R. Potentiation of NF-B-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells. Br J Pharmacol 2007; 152:891-902
47. Church MK. Non H1-receptor effects of antihistamines. Clin Exp Allergy 1999; 29:39-48
48. Bousquet J, Lebel B, Chanal I, Morel A, Michel FB. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82(5 Pt 1):881-887
49. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32:489-498
50. Zitt MJ. The role of nonsedating antihistamines in asthma therapy. Allergy Asthma Proc 2003; 24:239-252
51. Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F, Kontou-Fili K, Malling HJ, van Cauwenberge P, Canonica GW. The clinical safety of H1-receptor antagonists: an EAACI position paper. Allergy 1996; 51:666-675
52. Simons FE. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy 1999; 29(Suppl. 3):98-104
53. Busse WW, Middleton E, Storms W, Dockhorn RJ, Chu TJ, Grossman J, Weiler JM, Bronsky EA, Mansfield LE, Bell TD, Hemsworth GR, Perhach JL, DEletto TA, Dam A. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 1996; 153:122-127
54. Aubier M, Neukirch C, Peiffer C, Melac M. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001; 56:35-42
55. Wilson AM. The role of antihistamines in asthma management. Treat Respir Med 2006; 5:149-158
56. Pasquali M, Baiardini I, Rogkakou A, Riccio AM, Gamalero C, Descalzi D, Folli C, Passalacqua G, Canonica GW. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006; 36:1161-1167
57. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004; 113: 415-419
58. Fuhlbrigge AL, Adams RJ. The effect of treatment of allergic rhinitis on asthma morbidity, including emergency department visits. Curr Opin Allergy Clin Immunol 2003; 3:29-32
59. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57-62
60. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89: 485-491
61. Baena-Cagnani CE, Berger WE, DuBuske LM, Gurné SE, Stryszak P, Lorber R, Danzig M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003; 130:307-313
62. Nathan RA, Finn AF Jr., LaForce C, Ratner P, Chapman D, de Guia EC, Hewlett D, Kramer B. Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. Ann Allergy Asthma Immunol 2006; 97:389-396
63. Grant JA, Nicodemus CF, Findlay SR, Glovsky MM, Grossman J, Kaiser H, Meltzer EO, Mitchell DQ, Pearlman D, Selner J. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95(5 Pt. 1):923-932
64. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440-446
65. Reinartz SM, Overbeek SE, Kleinjan A, van Drunen CM, Braunstahl GJ, Hoogsteden HC, Fokkens WJ. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy 2005; 60: 1301-1307
66. Ruck LM, Rizzo CA, Anthes JC, Eckel S, Egan RW, Cuss FM, Hey JA. Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. Life Sci 2001; 68:2825-2834
67. Reicin A, White R, Weinstein SF, Finn AF Jr, Nguyen H, Peszek I, Geissler L, Seidenberg BC. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160:2481-2488